Xiamen Ade Biological Technology Co., Ltd. (hereinafter referred to as "the Company" or "Ade Biological") held the 11th meeting of the 4th Board of Directors on April 14, 2026, where it reviewed and approved the proposal on the use of idle self-owned funds for cash management. The Company agrees to use no more than RMB 1.8 billion of idle self-owned funds for cash management, with a term of 12 months starting from August 16, 2026. This proposal is subject to approval by the shareholders' meeting.
During the validity period of the above amount and resolution, the funds may be used in a rolling manner, and the management team is authorized to exercise decision-making power regarding this fund management, with the finance department responsible for handling related matters. The specific situation is announced as follows: